Morgan Stanley Maintains Overweight on Evommune, Lowers Price Target to $26

Benzinga Newsdesk www.benzinga.com Negative 57.8%

Neg 57.8% Neu 0% Pos 0%

Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and lowers the price target from $55 to $26.